In the News

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in <i>JAMA Oncology</i>.

Innovative imaging techniques shed light on intestinal damage that occurs after bone marrow transplant.

Results from a study of women with breast and ovarian cancer show surprisingly low rates of genetic testing.

MSK researchers developed an artificial intelligence system to detect cancer on digitized microscope slides.

Sometimes a BRCA mutation is just along for the ride, rather than driving a tumor’s development.

An MSK geriatrician discusses the importance of helping older people with cancer manage their treatment and symptoms.

Learn about George Bosl, who will become MSK's first ombudsperson.

A new imaging technology developed at MSK allows researchers to focus on genes as they are copied into messenger RNA.

An FDA-approved drug used to treat leukemia can serve as a temporary off switch for CAR T cells, MSK scientists have found.

The genome-editing technique uncovered several genes previously not known to influence embryonic development.